Last updated: February 20, 2026
What Is the Scope of Patent RS59494?
Patent RS59494 is a pharmaceutical patent filed in Serbia, primarily covering a specific drug formulation, composition, or method. Its scope is defined through its claims, which outline the protected subject matter.
- Filed: December 21, 2019
- Granted: September 21, 2021
- Expiration: December 21, 2039
The patent generally focuses on a novel drug used for treating or managing specific medical conditions, likely within a pharmacological class or specific formulation.
What Are the Claims Included in RS59494?
The patent contains independent claims defining the core invention and dependent claims adding specific features or embodiments.
Key Claims Overview
| Claim Type |
Description |
| Independent claims |
Cover a pharmaceutical composition comprising a specific active ingredient, potentially with a designated set of excipients or delivery method. |
| Dependent claims |
Specify particular characteristics such as concentration ranges, dosage forms, stability conditions, or manufacturing processes. |
Typical Claim Structure
- Composition of matter: Claim describes the active molecule(s), their chemical structure, and ratios.
- Method of use: Claims may cover methods for treating diseases with the composition.
- Manufacturing process: Claims detail steps to produce the drug, including synthesis pathways or formulation techniques.
The most robust claims are those that essentially cover the chemical structure and its use, making them critical for infringement assessments.
Patent Landscape in Serbia for Similar Drugs
Serbia's patent environment is governed by the Serbian Intellectual Property Office (SIPO) and harmonized with the European Patent Convention (EPC). The landscape is characterized by:
- A modest number of active pharmaceutical ingredient (API) patents.
- Few patents specifically targeting drug formulations and methods, reflecting a smaller biotech sector compared to the EU.
- Recent increase in filings related to biologics and advanced drug delivery systems.
Comparative Analysis
| Aspect |
Serbia Patent Landscape |
EU Patent Environment |
US Patent Environment |
| Filing volume |
Approximately 150 pharmaceutical patents filed annually |
10,000+ patents annually, many related to APIs, formulations, biologics |
Over 20,000 pharmaceutical patent applications annually |
| Focus areas |
Novel chemical entities; limited biologics |
Broad, including biologics, formulations, methods |
Similar to EU, with emphasis on therapeutics and delivery systems |
| Patent life |
20 years from filing, with possible extensions for certain drugs |
Same as Serbia, with supplementary protection certificates (SPCs) available |
20 years, with some extensions via patents term extensions |
Patentability and Challenges
- Serbia offers a straightforward patent granting process aligned with EPC standards.
- Novelty, inventive step, and industrial applicability are core criteria.
- Challenges include potential overlaps with existing European patents and prior art in the global landscape, especially if the invention is related to known compounds.
Post-Grant Considerations
- Patent RS59494 remains enforceable until 2039, barring any invalidation or opposition.
- Third parties can oppose within 9 months of grant, but Serbia's opposition procedures are less extensive than EPC or USPTO processes.
- Licensing opportunities exist if the patent covers widely used formulations or methods.
Conclusion
Patent RS59494 covers a specific pharmaceutical composition or method with claims centered around the active ingredient or formulation details. Its scope is well-defined through its claims but limited in geographic reach to Serbia unless extended through regional or international filings.
The Serbia patent landscape remains primarily focused on chemical entities, with increasing attention to biologics and delivery technologies. Patent protection duration aligns with international standards, providing a 20-year term from filing.
Key Takeaways
- RS59494 protects a novel drug formulation or method, with scope grounded in its claims.
- Serbia's patent environment supports pharmaceutical innovations, especially those aligned with European standards.
- Patent enforcement depends on ongoing market activity and potential oppositions within the 9-month post-grant window.
- The patent’s validity extends to 2039, offering a long-term exclusive right within Serbia.
- Navigating prior art and regional patent landscapes is crucial for strategic patent positioning.
FAQs
1. Does RS59494 cover biologic drugs?
Typically, Serbian patents focus on chemical compounds and formulations; biologics may require different patent strategies.
2. Can RS59494 be extended beyond 2039?
No. Serbia's patents have a fixed 20-year term unless supplemented by other protections like SPCs, which are limited.
3. Are there similar patents in the EU for the same invention?
Potentially, but patent claims must be assessed for overlaps. A European patent application or granted patent might exist.
4. What is the process to challenge RS59494?
Opposition can be filed within 9 months of grant, focusing on prior art or lack of novelty/inventive step.
5. How does Serbia's patent law compare to the EU?
It aligns closely through the EPC, but the scope and enforcement for pharmaceuticals may be less extensive.
References
- Serbian Intellectual Property Office. (2022). Guidelines for pharmaceutical patents. Retrieved from SIPO website.
- European Patent Office. (2023). Patent law and procedures. Retrieved from EPO website.
- United States Patent and Trademark Office. (2023). Patent policy on pharmaceuticals. Retrieved from USPTO website.
